Differential effects of angiotensin II and transforming growth factor β on the production of heparan sulfate proteoglycan by mesangial cells in vitro

Journal of the American Society of Nephrology

Volumn 7, Issue 7, 1996, Pages 1015-1023

  Van Det, Nicole F ^a   Tamsma, Jouke T ^a   Van Den Born, Jacob ^b   Verhagen, Nicole A M ^a   Van Den Heuvel, Lambert P W J ^b   Löwik, Clemens W G M ^a   Berden, Jo H M ^b   Bruijn, Jan A ^a   Daha, Mohamed R ^a   Van Der Woude, Fokko J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Extracellular matrix; Glomerular diseases; Glomerular mesanglum; Heparan sulfate proteoglycan; Onglotensin converting enzyme

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCOSAMINOGLYCAN; NEUTRALIZING ANTIBODY; PERLECAN; PROTEOHEPARAN SULFATE; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; BASEMENT MEMBRANE; CELL PROLIFERATION; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; GLOMERULOPATHY; HUMAN; HUMAN CELL; MESANGIUM; MESANGIUM CELL; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PROTEINURIA; RECEPTOR BLOCKING; SULFATION;

EID: 9844232626     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. van den Born J, van den Heuvel LPWJ, Bakker MAH, et al.: Distribution of GBM heparan sulfate proteoglycan core protein and side chains in human glomerular diseases. Kidney Int 1993;43:454-463.
2. Vernier RL, Klein DJ, Sisson SP, Mahan JD, Oegema TR, Brown DM: Heparan sulphate-rich anionic sites in the human glomerular basement membrane. N Engl J Med 1983;309:1003-1009.
3. Tamsma JT, van den Born J, Bruijn JA, et al.: Expression of glomerular extracellular matrix components in human diabetic nephropathy: Decrease of heparan sulphate in the glomerular basement membrane. Diabetologia 1994;37:313-320.
4. Gambaro G, Venturini AP, Noonan DM, et al.: Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. Kidney Int 1994;46: 797-806.
5. Myrup B, Hansen PM, Jensen T, et al.: Effect of low-dose heparin on urinary albumin excretion in insulin-dependent diabetes mellitus. Lancet 1995;345:421-422.
6. Tamsma JT, van der Woude FJ, Lemkes HHPJ: Effect of sulfated glycosaminoglycans on albuminuria in patients with overt diabetic (type I) nephropathy. Nephrol Dial Transplant 1996;11:182-185.
7. Anderson S, Rennke HG, Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension. J Clin Invest 1986;77:1993-2000.
8. Fogo A, Yoshida Y, Glick AD, Homma T, Ichikawa I: Serial micropuncture analysis of glomerular function in two rat models of glomerulosclerosis. J Clin Invest 1988; 82:322-330.
9. Anderson S, Meyer TW, Rennke HG, Brenner BM: Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 1985;75: 612-619.
10. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1465-1472.
11. Ray P, Agyuilera G, Kopp JB, Horikoshi S, Klotman PE: Angiotensin II receptor-mediated proliferation of cultured human mesangial cells. Kidney Int 1991;40:764-771.
12. Sraer JD, Sraer J, Ardaillou R, Mimoune D: Evidence for renal glomerular receptors for angiotensin II. Kidney Int 1974;6:241-246.
13. Zhou J, Ernsberger P, Douglas JG: Angiotensin II receptor subtypes in rat renal mesangial cells [Abstract]. FASEB (Fed Am Soc Exp Biol) J 1991;5:870A.
14. Kagami S, Border WA, Miller DE, Noble NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994;93:2431-2437.
15. Border WA, Ruoslahti E: Transforming growth factor-β in disease: The dark side of tissue repair. J Clin Invest 1992;90:1-7.
16. Roberts AB, Heine UI, Flanders KC, Sporn MB: Transforming growth factor-β: Major role in regulation of extracellular matrix. Ann NY Acad Sci 1990;580:225-232.
17. Roberts AB, Mc Cune BK, Sporn MB: TGF-β: Regulation of extracellular matrix. Kidney Int 1992;41:557-559.
18. Wahl SM: Transforming growth factor beta (TGF-β) in inflammation: A cause and a cure. J Clin Immunol 1992;12:61-74.
19. Okuda S, Nakamura T, Yamamoto T, Ruoslahti E, Border WA: Dietary protein restriction rapidly reduces transforming growth factor β1 expression in expression in experimental glomerulonephritis. Proc Natl Acad Sci USA 1991;88:9765-9769.
20. Yoshioka K, Takemura T, Murakami K, et al.: Transforming growth factor-β protein and mRNA in normal and diseased human kidneys. Lab Invest 1993;68:154-163.
21. Kagami S, Border WA, Ruoslahti E, Noble NA: Coordinate expression of β1 integrins and transforming growth factor-β-induced matrix proteins in glomerulonephritis. Lab Invest 1993;69:68-76.
22. Okuda S, Languino LR, Ruoslahti E, Border WA: Elevated expression of transforming growth factor-β and proteoglycan production in experimental glomerulonephritis. J Clin Invest 1990;86:453-462.
23. Border WA, Noble NA, Yamamoto T, et al.: Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature (Lond) 1992;360:361-364.
24. Gansevoort RT, de Zeeuw D, de Jong PE: Dissociation between the course of the hemodynamic and antiproteinuric effects of angiotensin I converting enzyme inhibition. Kidney Int 1993;44:579-584.
25. van den Born J, van den Heuvel LPWJ, Bakker MAH, Veerkamp JH, Assmann KJM, Berden JHM: Monoclonal antibodies against the protein core and glycosaminoglycan side chain of glomerular basement membrane heparan sulfate proteoglycan: Characterization and immunohistological application in human tissues. J Histochem Cytochem 1994;42:89-102.
26. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA: Expression of transforming growth factor β is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 1993;90:1814-1818.
27. Muller EW, Kim Y, Michael AF, Vernier RL, van der Hem GK, van der Woude FJ: Explantation of mesangial cell "hillocks": A method for obtaining human mesangial cells in culture. Int J Exp Pathol 1992;73:9-20.
28. van Det NF, van den Born J, Tamsma JT, et al.: Proteoglycan production by human glomerular visceral epithelial cells and mesangial cells in vitro. Biochem J 1995; 307:759-768.
29. Müller GA, Müller G: Characterization of renal antigens on distinct parts of the human nephron by monoclonal antibodies. Klin Wochenschr 1983;61:893-902.
30. Lucas C, Bald LN, Fendly BM, et al.: The autocrine production of transforming growth factor-beta 1 during lymphocyte activation. A study with monoclonal antibody based ELISA. J Immunol 1995;145:1415-1422.
31. Hoffmann P. In: Quintarelli G, Ed. The Chemical Physiology of Mucopolysaccharides. London: J&A Churchill Ltd; 1968:33-49.
32. Brown DM, Michael AF, Oegema TR: Glycosaminoglycan synthesis by glomeruli in vivo and in vitro. Biochem Biophys Acta 1981;674:96-104.
33. Oegema TR, Hascall VC, Eisenstein R: Characterization of bovine aorta proteoglycan extracted with guanidine hydrochloride in the presence of protease inhibitors. J Biol Chem 1979;254:1312-1318.
34. Carney SL. Carbohydrate Analysis: A Practical Approach. Oxford: IKC Press; 1987:97-141.
35. Lowik CWGM, Alblas MJ, van de Ruit M, Papapoulos SE, van der Pluim G: Quantification of adherent and nonadherent cells cultured in 96-well plates using the supravital stain neutral red. Anal Biochem 1993;231: 426-433.
36. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning, A laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1983.
37. Church GM, Gilbert W: Genomic sequencing. Proc Natl Acad Sci USA 1984;81:1991-1995.
38. Noonan DM, Horigan EA, Ledbetter SR, et al.: Identification of cDNA clones encoding different domains of the basement membrane heparan sulfate proteoglycan. J Biol Chem 1988;263:16379-16387.
39. Anderson P, Do YS, Hsueh WA: Angiotensin causes mesangial cell hypertrophy. Hypertension (Dallas) 1993; 21:29-35.
40. Morelli E, Loon N, Meyer T, Peters W, Myers B: Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy. Diabetes 1990;39:76-82.
41. Reddi A, Ramamurthi R, Miller M, Dhuper S, Lasker N: Enalapril improves albuminuria by preventing glomerular loss of heparan sulfate in diabetic rats. Biochem Med Metab Biol 1991;40:119-131.
42. Wapstra FH, van den Born J, Berden JHM, de Jong PE, de Zeeuw D: ACE-inhibition restores loss of heparan sulfate (HS) in the glomerular basement membrane (GBM) of rats with established adriamycin (ADM) nephrosis [Abstract]. J Am Soc Nephrol 1994;5:797A.
43. Wolf G, Haberstroh U, Neilson EG: Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am J Pathol 1992;140:95-107.
44. Ray PE, Bruggeman LA, Horikoshi S, Aguilera G, Klotman PE: Angiotensin II stimulates human fetal mesangial cell proliferation and fibronectin biosynthesis by binding to AT 1 receptors. Kidney Int 1994;45:177-184.
45. Rapraeger AC, Krufka A, Olwin BB: Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science (Wash DC) 1991; 252:1705-1707.
46. Maccarana M, Casu B, Lindahl U: Minimal sequence in heparin/heparan sulfate required for binding of basic fibroblast growth factor. J Biol Chem 1993;268:23898-23905.
47. Guimond S, Maccarana M, Olwin BB, Lindahl U, Rapraeger AC: Activating and inhibitory heparin sequences for FGF-2 (basic FGF). J Biol Chem 1993;268:23906-23914.
48. Raij L, Keane WF: Glomerular mesangium: Its function and relationship to angiotensin II. Am J Med 1985;79: 24-30.
49. Mandai AK, Lyden TW, Saklayen MG: Heparin lowers blood pressure: Biological and clinical perspectives. Kidney Int 1995;47:1017-1030.
50. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E: Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1. Nature (Lond) 1990;346:371-374.
51. Wahl SM: Transforming growth factor β: The good, the bad, and the ugly. J Exp Med 1994;180:1587-1590.
52. Chen JK, Hoshi H, Mc Keeman WL: Stimulation of human arterial smooth muscle cell chondroitin sulfate proteoglycan synthesis by transforming growth factor-β. In Vitro Cell & Dev Biol 1991;27A:6-12.
53. Border WA, Okuda S, Languino LR, Ruoslahti E: Transforming growth factor-β regulates production of proteoglycans by mesangial cells. Kidney Int 1990;37:689-695.
54. Pfeilschifter J, Huwiler A: A role for protein kinase C-∈ in angiotensin II stimulation of phospholipase D in rat mesangial cells. FEBS (Fed Eur Biochem Soc) Lett 1993; 331:267-271.
55. Mene P, Simonson MS, Dunn MJ: Phospholipid in signal transduction of mesangial cells. Am J Physiol 1989;256: F375-F386.
56. Griendling KK, Delafontaine P, Rittenhouse SE, Gimbrone MA, Alexander RW: Correlation of receptor sequestration with sustained diacylglycerol accumulation in angiotensin II stimulated cultured vascular smooth muscle cells. J Biol Chem 1987;262:14555-14562.